TY - JOUR
T1 - A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults
AU - Capella, Giovanni Luigi
AU - Frigerio, Elena
AU - Altomare, Gianfranco
PY - 2001
Y1 - 2001
N2 - Leukotriene receptor antagonists are recommended for the treatment of asthma, and have proved anecdotally successful even in atopic dermatitis. Standard treatments of atopic dermatitis are often unsatisfactory. Accordingly, we compared montelukast, 10 mg/day, with a combined regimen (orally administered cetirizine and clarythromycin, topical corticosteroids and hydrating preparations) for treatment of moderate-to-severe atopic dermatitis of adults. The trial was designed as a randomized single-blind study. SCORAD, eosinophilic cationic protein (ECP), eosinophilic protein X (EPX) serum levels were assessed at baseline and after 6 weeks in 32 adult patients with atopic dermatitis (16 treated with montelukast; 16 treated with the combined regimen). Similar improvements, evaluated in term of SCORAD reductions, were detected in both groups (Mann-Whitney, p <0.05), while ECP and EPX levels significantly reduced within each group (Welch's approximate t, p <0.05). We conclude that montelukast is as effective as the comparison combined regimen to treat atopic dermatitis of adults.
AB - Leukotriene receptor antagonists are recommended for the treatment of asthma, and have proved anecdotally successful even in atopic dermatitis. Standard treatments of atopic dermatitis are often unsatisfactory. Accordingly, we compared montelukast, 10 mg/day, with a combined regimen (orally administered cetirizine and clarythromycin, topical corticosteroids and hydrating preparations) for treatment of moderate-to-severe atopic dermatitis of adults. The trial was designed as a randomized single-blind study. SCORAD, eosinophilic cationic protein (ECP), eosinophilic protein X (EPX) serum levels were assessed at baseline and after 6 weeks in 32 adult patients with atopic dermatitis (16 treated with montelukast; 16 treated with the combined regimen). Similar improvements, evaluated in term of SCORAD reductions, were detected in both groups (Mann-Whitney, p <0.05), while ECP and EPX levels significantly reduced within each group (Welch's approximate t, p <0.05). We conclude that montelukast is as effective as the comparison combined regimen to treat atopic dermatitis of adults.
KW - Allergic rhinoconjunctivitis
KW - Asthma
KW - Atopic dermatitis
KW - Leukotriene receptor antagonists
KW - Montelukast
KW - SCORAD
UR - http://www.scopus.com/inward/record.url?scp=0035019380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035019380&partnerID=8YFLogxK
M3 - Article
C2 - 11358726
AN - SCOPUS:0035019380
VL - 11
SP - 209
EP - 213
JO - European Journal of Dermatology
JF - European Journal of Dermatology
SN - 1167-1122
IS - 3
ER -